These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3840437)

  • 1. Mean time and first-pass metabolism.
    Brockmeier D; Ostrowski J
    Eur J Clin Pharmacol; 1985; 29(1):45-8. PubMed ID: 3840437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of first-pass metabolism on metabolite mean residence time determination after oral administration of parent drug.
    Chan KK; Gibaldi M
    Pharm Res; 1990 Jan; 7(1):59-63. PubMed ID: 2300537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma.
    Alván G; Borga O; Lind M; Palmér L; Siwers B
    Eur J Clin Pharmacol; 1977 Mar; 11(3):219-24. PubMed ID: 852498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-pass elimination. Basic concepts and clinical consequences.
    Pond SM; Tozer TN
    Clin Pharmacokinet; 1984; 9(1):1-25. PubMed ID: 6362950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mean residence time of oral drugs undergoing first-pass and linear reversible metabolism.
    Cheng H; Jusko WJ
    Pharm Res; 1993 Jan; 10(1):8-13. PubMed ID: 8430064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A general model of metabolite kinetics following intravenous and oral administration of the parent drug.
    Weiss M
    Biopharm Drug Dispos; 1988; 9(2):159-76. PubMed ID: 3370305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of stable isotope labelled drugs in clinical pharmacology: with illustrations from studies on the disposition of propranolol and nortriptyline in man.
    Gaffney TE; Knapp D; Walle T; Privitera P; Saelens D
    South Med J; 1974 Aug; 67(8):990-1002. PubMed ID: 4854875
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of molsidomine in humans.
    Ostrowski J; Resag K
    Am Heart J; 1985 Mar; 109(3 Pt 2):641-3. PubMed ID: 3838399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ratio of first to zeroth moments of the plasma profile of an oral drug undergoing first-pass and linear reversible metabolism.
    Cheng H
    Biopharm Drug Dispos; 1995 Dec; 16(9):791-6. PubMed ID: 8580402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing.
    Brockmeier D; von Hattingberg HM
    Arzneimittelforschung; 1982; 32(3):248-51. PubMed ID: 6896279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of observed and predicted first-pass metabolism of nortriptyline in humans.
    Niazi S
    J Pharm Sci; 1976 Oct; 65(10):1535-6. PubMed ID: 978417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Human pharmacokinetics of molsidomine].
    Singlas E; Martre H
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):503-9. PubMed ID: 6364946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.
    Bergstrand R; Vedin A; Wilhelmsson C; Peterson LE; Chamberlain J; Dell D; Stevens LA; Ostrowski J
    Eur J Clin Pharmacol; 1984; 27(2):203-8. PubMed ID: 6548711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method for calculating the mean absorption time of drugs undergoing reversible and first-pass metabolism.
    Cheng H; Shum L
    Biopharm Drug Dispos; 1993 Jan; 14(1):71-9. PubMed ID: 8427946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data.
    Somogyi A; Eichelbaum M; Gugler R
    Eur J Clin Pharmacol; 1982; 22(1):85-90. PubMed ID: 7094978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theoretical relationships between area under the curve and route of administration of drugs and their precursors for evaluating sites and pathways of metabolism.
    Pang KS; Gillette JR
    J Pharm Sci; 1978 May; 67(5):703-4. PubMed ID: 641815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.
    Ostrowski J; Gaul G; Voegele D; Brockmeier D; Resag K
    Eur J Clin Pharmacol; 1985; 28(5):611-3. PubMed ID: 3899679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-pass metabolism of nortriptyline in man.
    Gram LF; Overo KF
    Clin Pharmacol Ther; 1975 Sep; 18(3):305-14. PubMed ID: 1164819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of sequential metabolism. Contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite.
    Pang KS
    Drug Metab Dispos; 1995 Feb; 23(2):166-77. PubMed ID: 7736907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A convenient method for estimating the quantity of drug eliminated by the routes other than hepatic metabolism and renal excretion and the fraction of drug that reaches the "first pass" after oral administration.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):828-33. PubMed ID: 16489605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.